{
    "clinical_study": {
        "@rank": "122717", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "H7N9c low dose with adjuvant"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "H7N9c medium dose with adjuvant"
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "H7N9c high dose with adjuvant"
            }, 
            {
                "arm_group_label": "Group D", 
                "arm_group_type": "Experimental", 
                "description": "H7N9c high dose without adjuvant"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluate the safety and immunogenicity of four different doses of H7N9 vaccination in adults\n      between the ages of 18 years and 65 years."
        }, 
        "brief_title": "Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "H7N9 Influenza", 
        "condition_browse": {
            "mesh_term": "Influenza, Human"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Healthy adult subject ages 18-64 years.\n\n          2. Individuals willing to provide written informed consent\n\n          3. Individuals in good health.\n\n          4. Individuals who can comply with study procedures and follow-up.\n\n        Exclusion Criteria:\n\n          1. Individuals with history of cognitive or behavioral impairment or psychiatric\n             disease,\n\n          2. Individuals unable to understand and follow study procedures,\n\n          3. History of significant illness,\n\n          4. History of chronic medical condition or progressive disease,\n\n          5. Allergy to any vaccine component or adverse event related to a vaccine component,\n\n          6. Impairment/alteration of the immune system,\n\n          7. Presence of progressive or severe neurological disorder,\n\n          8. Pregnant or breast-feeding,\n\n          9. Female of Child-bearing potential unwilling to use acceptable method of birth\n             control,\n\n         10. Presence of medically significant cancer,\n\n         11. Receipt of investigational product within 30 day prior to entry into the study,\n\n         12. History of previous or suspected illness from avian flu caused by H7N9 virus,\n\n         13. History of H7 vaccination,\n\n         14. Body temperature of greater than or equal to 38.0\u00b0C (100.4\u25e6F) and/or acute illness\n             within 3 days of intended study vaccination,\n\n         15. Receipt of any flu vaccination 2 weeks before study entry or 4 weeks after study\n             vaccination,\n\n         16. Receipt of any vaccination 2 weeks before study entry or 4 weeks after study\n             vaccination,\n\n         17. History of drug or alcohol abuse within the past 2 years,\n\n         18. Body Mass Index (BMI) greater than or equal to 35kg/m2,\n\n         19. Individuals conducting the study or their immediate family members."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01928472", 
            "org_study_id": "V131_01"
        }, 
        "intervention": [
            {
                "arm_group_label": "Group A", 
                "intervention_name": "H7N9c low dose with adjuvant", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group B", 
                "intervention_name": "H7N9c medium dose with adjuvant", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group C", 
                "intervention_name": "H7N9c high dose with adjuvant", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group D", 
                "intervention_name": "H7N9c high dose without adjuvant", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Influenza, H7N9, Vaccine", 
        "lastchanged_date": "February 25, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92108"
                    }, 
                    "name": "Site 04: Accelovance"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Melbourne", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32935"
                    }, 
                    "name": "Site 01: Accelovance"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Peoria", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "61602"
                    }, 
                    "name": "Site 02: Accelovance"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rockville", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "20850"
                    }, 
                    "name": "Site 03: Accelovance"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84109"
                    }, 
                    "name": "Site 05: Janet Lewis"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84121"
                    }, 
                    "name": "Site 06: Janet Lewis"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Phase I Multi-center, Observer-Blind, Randomized Dose-Ranging Study of Adjuvanted and Non-Adjuvanted Cell Culture-Derived, Inactivated A/H7N9 Monovalent Subunit Influenza Virus Vaccine (H7N9c) in Adults 18 to <65 Years", 
        "overall_official": {
            "affiliation": "Novartis Vaccines", 
            "last_name": "Novartis Vaccines and Diagnostics", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate hemagglutination inhibition (HI) assay results for each H7N9 vaccine group after 2 vaccine doses, with descriptive summaries of the endpoints for Day 43.", 
                "measure": "Geometric Mean Titre (GMT), Geometric Mean Ration (GMR) and percentage of subjects achieving seroconversion", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and 43"
            }, 
            {
                "description": "To evaluate the safety and tolerability of each H7N9 vaccine group.", 
                "measure": "Percentage of subjects with solicited local adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1-7"
            }, 
            {
                "description": "To evaluate the safety and tolerability of each H7N9 vaccine group.", 
                "measure": "Percentage of subjects with solicited systematic adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 22-29"
            }, 
            {
                "description": "To evaluate the safety and tolerability of each H7N9 vaccine group.", 
                "measure": "Percentage of subjects with unsolicited adverse events and percentage of subjects with serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Day 1-336"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01928472"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To evaluate hemagglutination inhibition (HI) assay results for each H7N9c vaccine group at Day 22 and To evaluate hemagglutination inhibition (HI) assay results for each H7N9c vaccine group for persistence at 6 and 12 months", 
                "measure": "GMT, GMR and percentage of subjects achieving seroconversion by HI", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 22, 183, 366"
            }, 
            {
                "description": "Microneutralization (MN) and other serologic assays for H7N9 may be evaluated", 
                "measure": "GMT, GMR and percentage of subjects achieving seroconversion by MN", 
                "safety_issue": "No", 
                "time_frame": "Day 1, 22, 43, 183, 366"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Vaccines", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}